MARSHALL WACE, LLP - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 62 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
MARSHALL WACE, LLP ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$877,330
+7211.1%
29,500
+6529.2%
0.00%
Q4 2021$12,000
-80.6%
445
-89.5%
0.00%
-100.0%
Q1 2020$62,000
-92.5%
4,246
-92.3%
0.00%
-85.7%
Q3 2019$829,000
-3.3%
55,112
+61.0%
0.01%0.0%
Q2 2019$857,000
-44.7%
34,238
-49.7%
0.01%0.0%
Q1 2019$1,550,00068,1240.01%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q3 2019
NameSharesValueWeighting ↓
Versant Venture Management, LLC 2,030,616$31,028,0006.04%
5AM Venture Management, LLC 1,362,286$20,816,0003.75%
Burrage Capital Management LLC 272,393$4,162,0003.37%
Altium Capital Management LP 361,930$5,530,0001.54%
Vivo Capital, LLC 2,214,138$33,832,0001.19%
Bain Capital Life Sciences Investors, LLC 1,071,428$16,371,0000.93%
Perceptive Advisors 3,659,381$51,606,0000.65%
New Leaf Venture Partners, L.L.C. 141,000$2,154,0000.50%
DRIEHAUS CAPITAL MANAGEMENT LLC 2,003,688$30,616,0000.45%
Opaleye Management Inc. 188,000$2,873,0000.42%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders